9
Participants
Start Date
June 30, 2001
Primary Completion Date
September 30, 2008
Study Completion Date
September 30, 2008
Dextromethorphan and Caffeine
"All subjects received standard medical therapy with rhGH and at specified times low doses of the pharmacologic probes (e.g., caffeine and dextromethorphan) as surrogate markers to determine CYP450 activity. The only direct treatment effect measured was the biological response to rhGH."
Kosair Charities Pediatric Clinical Research Unit, Louisville
Children's Mercy Hospital and Clinics, Kansas City
University of California at San Diego, San Diego
Rainbow Babies and Children's Hospital, Cleveland
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
University of Louisville
OTHER